Loading...

Miragen Therapeutics

DB:1S1N
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1S1N
DB
$84M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Miragen Therapeutics has significant price volatility in the past 3 months.
1S1N Share Price and Events
7 Day Returns
-7.8%
DB:1S1N
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-53.1%
DB:1S1N
-9.2%
DE Biotechs
-6.7%
DE Market
1S1N Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Miragen Therapeutics (1S1N) -7.8% 0.4% -10.2% -53.1% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 1S1N underperformed the Biotechs industry which returned -9.2% over the past year.
  • 1S1N underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
1S1N
Industry
5yr Volatility vs Market
Related Companies

1S1N Value

 Is Miragen Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Miragen Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €2.461.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Miragen Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Miragen Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1S1N PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.10
NasdaqCM:MGEN Share Price ** NasdaqCM (2019-04-18) in USD $2.73
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Miragen Therapeutics.

DB:1S1N PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MGEN Share Price ÷ EPS (both in USD)

= 2.73 ÷ -1.10

-2.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Miragen Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Miragen Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Miragen Therapeutics's expected growth come at a high price?
Raw Data
DB:1S1N PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
12.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Miragen Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Miragen Therapeutics's assets?
Raw Data
DB:1S1N PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.66
NasdaqCM:MGEN Share Price * NasdaqCM (2019-04-18) in USD $2.73
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:1S1N PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MGEN Share Price ÷ Book Value per Share (both in USD)

= 2.73 ÷ 1.66

1.64x

* Primary Listing of Miragen Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Miragen Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Miragen Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Miragen Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1S1N Future Performance

 How is Miragen Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Miragen Therapeutics expected to grow at an attractive rate?
  • Unable to compare Miragen Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Miragen Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Miragen Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1S1N Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1S1N Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 12.5%
DB:1S1N Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 54.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1S1N Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1S1N Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 91 -1 3
2022-12-31 45 -38 4
2021-12-31 13 -55 4
2020-12-31 2 -56 3
2019-12-31 3 -48 3
DB:1S1N Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 8 -27 -33
2018-09-30 9 -26 -29
2018-06-30 10 -25 -26
2018-03-31 8 -27 -24
2017-12-31 4 -28 -27
2017-09-30 3 -24 -26
2017-06-30 3 -21 -24
2017-03-31 3 -19 -21
2016-12-31 3 -15 -17
2016-09-30 4 -14 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Miragen Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Miragen Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1S1N Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Miragen Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1S1N Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.04 0.42 -0.23 3.00
2022-12-31 -0.33 -0.05 -0.60 2.00
2021-12-31 -1.10 -0.66 -1.90 4.00
2020-12-31 -1.41 -0.77 -1.83 4.00
2019-12-31 -1.38 -0.93 -1.54 4.00
DB:1S1N Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.10
2018-09-30 -1.05
2018-06-30 -1.02
2018-03-31 -1.05
2017-12-31 -1.38
2017-09-30 -1.89
2017-06-30 -2.85
2017-03-31 -6.19
2016-12-31 -28.21
2016-09-30 -25.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Miragen Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Miragen Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Miragen Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1S1N Past Performance

  How has Miragen Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Miragen Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Miragen Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Miragen Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Miragen Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Miragen Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Miragen Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1S1N Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 8.39 -32.70 11.05
2018-09-30 9.10 -28.77 10.90
2018-06-30 9.79 -25.60 10.71
2018-03-31 8.33 -24.19 10.62
2017-12-31 4.00 -26.52 10.91
2017-09-30 3.32 -26.12 10.88
2017-06-30 2.63 -24.45 10.43
2017-03-31 3.02 -20.67 9.06
2016-12-31 3.48 -17.32 6.77
2016-09-30 3.96 -16.63 5.20
2015-12-31 5.00 -15.72 3.85
2014-12-31 7.64 -5.94 4.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Miragen Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Miragen Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Miragen Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Miragen Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Miragen Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1S1N Health

 How is Miragen Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Miragen Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Miragen Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Miragen Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Miragen Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Miragen Therapeutics Company Filings, last reported 3 months ago.

DB:1S1N Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 51.34 10.30 62.48
2018-09-30 60.72 10.21 70.53
2018-06-30 67.67 10.11 76.26
2018-03-31 72.71 10.02 78.10
2017-12-31 38.51 9.92 47.44
2017-09-30 38.99 3.37 42.81
2017-06-30 41.34 3.85 46.34
2017-03-31 47.99 4.32 54.27
2016-12-31 15.06 4.79 22.10
2016-09-30 20.47 5.10 25.60
2015-12-31 15.56 4.93 21.24
2014-12-31 3.24 0.00 5.11
  • Miragen Therapeutics's level of debt (20.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Miragen Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Miragen Therapeutics has sufficient cash runway for 2.3 years based on current free cash flow.
  • Miragen Therapeutics has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 25.5% each year.
X
Financial health checks
We assess Miragen Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Miragen Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1S1N Dividends

 What is Miragen Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Miragen Therapeutics dividends.
If you bought €2,000 of Miragen Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Miragen Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Miragen Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1S1N Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1S1N Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Miragen Therapeutics has not reported any payouts.
  • Unable to verify if Miragen Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Miragen Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Miragen Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Miragen Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Miragen Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Miragen Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1S1N Management

 What is the CEO of Miragen Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Marshall
COMPENSATION $2,189,483
AGE 54
TENURE AS CEO 2.2 years
CEO Bio

Dr. William Stuart Marshall, also known as Bill, Ph.D., Co-founded Miragen Therapeutics, Inc. in September 2007 and has been its Chief Executive Officer, President and Director since February 2017. Dr. Marshall is the Atlas Advisor at Atlas Venture L.P. Dr. Marshall was Vice President of Technology and Business Development for bioscience at Thermo Fisher Scientific Inc. from April 2005 to July 2007, where he led the Thermo Fisher Biosciences Division. He served as the Executive Vice President of Research & Operations and General Manager at Fisher Scientific International/Dharmacon from August 2002 to April 2005. Dr. Marshall served as Executive Vice President of Research, Development & Production and Site Director at GE Healthcare Dharmacon, Inc. (a/k/a Dharmacon, Inc.). He was one of the Scientific Founders of Dharmacon, Inc. Dr. Marshall was instrumental in leading the chemistry, biology and bioinformatics research, which led to the development of the industry's most effective siRNA design algorithm and novel chemical modifications to enhance siRNA specificity and stability. Prior to joining Dharmacon, he served in several capacities at Amgen, Inc., from 1992 to 2002, as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. He has more than 15 years' experience in the biochemistry environment, including 10 years in industrial biotechnology. Dr. Marshall serves as a Director of FluoroFinder LLC. He serves as a Member of Business Advisory Board at AmideBio, LLC. Dr. Marshall serves as Independent Director of BiOptix Inc. He also led the development of peptide library approaches for lead discovery and development via carrier protein fusion and peptidomimetics. He is an author and co-author of 30 research papers and 10 patents. Dr. Marshall received a Bachelor of Science in Biochemistry from the University of Wisconsin-Madison and a PhD in Chemistry from the University of Colorado at Boulder.

CEO Compensation
  • Bill's compensation has increased whilst company is loss making.
  • Bill's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Miragen Therapeutics management team in years:

2.4
Average Tenure
59
Average Age
  • The tenure for the Miragen Therapeutics management team is about average.
Management Team

Bill Marshall

TITLE
Co-Founder
COMPENSATION
$2M
AGE
54
TENURE
2.2 yrs

Adam Levy

TITLE
Chief Business Officer
COMPENSATION
$1M
AGE
40
TENURE
2.2 yrs

Paul Rubin

TITLE
Executive Vice President of Research & Development
COMPENSATION
$1M
AGE
64
TENURE
2.4 yrs

Eric Olson

TITLE
Co-Founder & Chairman of Scientific Advisory Board

Michael Bristow

TITLE
Co-Founder & Member of the Scientific Advisory Board
AGE
73
TENURE
13.3 yrs

Marvin Caruthers

TITLE
Scientific Advisory Board Member
AGE
78
TENURE
13.3 yrs

Jason Leverone

TITLE
CFO, Treasurer & Secretary
COMPENSATION
$260K
AGE
44
TENURE
2.2 yrs

Aimee Jackson

TITLE
Vice President of Research
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Miragen Therapeutics board of directors in years:

2.2
Average Tenure
60
Average Age
  • The average tenure for the Miragen Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jeff Hatfield

TITLE
Chairman of the Board
COMPENSATION
$207K
AGE
60
TENURE
0.3 yrs

Bill Marshall

TITLE
Co-Founder
COMPENSATION
$2M
AGE
54
TENURE
2.2 yrs

Eric Olson

TITLE
Co-Founder & Chairman of Scientific Advisory Board

Michael Bristow

TITLE
Co-Founder & Member of the Scientific Advisory Board
AGE
73

Marvin Caruthers

TITLE
Scientific Advisory Board Member
AGE
78

Tom Hughes

TITLE
Director
COMPENSATION
$152K
AGE
58
TENURE
2.2 yrs

Kevin Koch

TITLE
Director
COMPENSATION
$150K
AGE
58
TENURE
2.2 yrs

Joe Turner

TITLE
Director
COMPENSATION
$365K
AGE
66
TENURE
2.2 yrs

Victor Ambros

TITLE
Scientific Advisory Board Member

Douglas Mann

TITLE
Member of the Scientific Advisory Board
TENURE
9.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Oct 18 Buy Thomas Hughes Individual 11. Oct 18 11. Oct 18 10,000 €4.13 €41,282
X
Management checks
We assess Miragen Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Miragen Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1S1N News

Simply Wall St News

1S1N Company Info

Description

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Details
Name: Miragen Therapeutics, Inc.
1S1N
Exchange: DB
Founded: 2006
$75,095,519
30,921,219
Website: http://www.miragen.com
Address: Miragen Therapeutics, Inc.
6200 Lookout Road,
Boulder,
Colorado, 80301,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MGEN Common Stock Nasdaq Capital Market US USD 14. Feb 2017
DB 1S1N Common Stock Deutsche Boerse AG DE EUR 14. Feb 2017
LSE 0K1R Common Stock London Stock Exchange GB USD 14. Feb 2017
Number of employees
Current staff
Staff numbers
79
Miragen Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:30
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.